Language selection

Search

Patent 1315689 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1315689
(21) Application Number: 548964
(54) English Title: QUARTERNARY DERIVATIVES OF NOROXYMORPHONE WHICH RELIEVE NAUSEA AND EMESIS
(54) French Title: DERIVES QUATERNAIRES DE LA NOROXYMORPHONE SOULAGEANT LA NAUSEE ET LE VOMISSEMENT
Status: Expired
Bibliographic Data
(52) Canadian Patent Classification (CPC):
  • 167/245
(51) International Patent Classification (IPC):
  • A61K 31/485 (2006.01)
  • C07D 489/08 (2006.01)
(72) Inventors :
  • GOLDBERG, LEON I. (United States of America)
(73) Owners :
  • UNIVERSITY OF CHICAGO (United States of America)
(71) Applicants :
(74) Agent: FETHERSTONHAUGH & CO.
(74) Associate agent:
(45) Issued: 1993-04-06
(22) Filed Date: 1987-10-09
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
092,470 United States of America 1987-09-03

Abstracts

English Abstract




- 9 -

QUATERNARY DERIVATIVES OF NOROXYMORPHONE
WHICH RELIEVE NAUSEA AND EMESIS

ABSTRACT OF THE DISCLOSURE

Quaternary derivatives of noroxymorphone are used
to prevent or relieve nausea and emesis associated with
the use of narcotic analgesics without interfering with
the analgesic activity of the drugs. A particularly
preferred compound is methylnaltrexone. The compound is
administered in a concentration between 0.05 mg/kg and
1.0 mg/kg prior to or concurrently with the
administration of the narcotic analgesic.


Claims

Note: Claims are shown in the official language in which they were submitted.



-7- 40355-99

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. Use of a compound of the formula:


Image



wherein
R is allyl or a related radical; and
X is the anion of an acid;
prior to or simultaneously with administration of a
narcotic analgesic to prevent or relieve nausea and emesis
associated with the use of the narcotic analgesics in warm-
blooded animals.

2. Use as claimed in claim 1 in which R is chloroallyl,
cyclopropyl-methyl or propargyl.

3. Use as claimed in claim 1 in which X is a choride,
bromide, iodide or methylsulfate anion.

4. Use as claimed in claim 1, where the compound is
is in an amount between 0.05 mg/kg and about 1.0mg/kg
of animal body weight.

5. Use as claimed in claim 1, as an enterally
administered compound.


-8-
6. Use as claimed in claim 1, as parenterally
administered compound.

7. Use as claimed in claim 6, as an injectably
administered compound.

8. Use as claimed in claim 1, prior to the
administration of the narcotic analgesic.

9. Use as claimed in claim 1, up to about two hours
prior to the administration of the narcotic analgesic.

10. Use as claimed in claim 1, concurrently with the
administration of the narcotic analgesic.

11. Use of methylnaltrexone to prevent or relieve
nausea and emesis associated with the use of a narcotic
analgesic in war-blooded animals.

12. Use as claimed in claim 11 in an amount of between
0.05 mg/kg of animal body weight and about 1.0 mg/kg of
animal body weight simultaneously with or up to about
two hours prior to the time of administration of the
narcotic analgesic.

13. Use as claimed in claim 12, as a parenterally
administered compound.


-8a-
14. A pharmaceutical composition for preventing or
relieving nausea and emesis comprising a narcotic analgesic
in combination with at least one quaternary derivative of
noroxymorphone:


Image


wherein
R is allyl or a related radical; and
X is the anion of an acid;
and wherein the quaternary derivative of noroxymorphone is
present in an amount effective to prevent or relieve nausea
induced by the narcotic analgesic.

15. A pharmaceutical composition as claimed in claim 12 in
which R is chloroallyl, cyclopropyl-methyl or propargyl.

16. A composition as claimed in claim 12 in which X is a
chloride, bromide, iodide or methylsulfate anion.

17. A composition according to claim 14, wherein the
quaternary derivative of noroxymorphone is present in a
unit dose of between about 0.05 mg and about 1.0 mg for
each 1 mg of morphine.

18. A composition as claimed in claim 14, wherein the
narcotic analgesic is morphine.


-8b-

19. A composition as claimed in claim 14, wherein the
quaternary derivative of noroxymorphone is
methylnaltrexone.

Description

Note: Descriptions are shown in the official language in which they were submitted.


~3~ 3
~0355--99
-- 1 --
OUATERNARY DERIVATIVES OF NOROXYMORPHO
~HICH RELIEVE NAUSEA AND EMESIS
The administration of therapeutic doses of morphine and
other clinically useful narcotie analgesies is often
aecompanied by unpleasant side effects on the gas-tro-
intestinal system. For instance, morphine and related
opiates such as meperidine and methadone may reta~d
intestinal mobility by causing con-traetions of -the small
bowel eireular smooth musele.

Morphine and related narcoties may also induce nausea
and increased mobility of the gastro-intes-tinal tract
resulting in emesis or vomiting~ These side effects are
eaused by direet stimulation of the chemoreeeptor trigger
zone for emesis in the area postrema of the medulla. (Goodman
and Bilman, The Pharmaeologieal Basis of Theraneu~ics, p. 502
[6`th ed. 1980]). Studies have shown that morphine and other
nareoties eause emesis in dogs. For example, Wang and
Glaviano, JPET 111:329-334 ~9143~, reported that
administration of 0.5 mg/kg of morphine intravenously to 12
dogs resulted in emesis in 9 dogs within an average of 2.
minutes. (Mg/kg refers to milligrams of morphine per
kilograms of body weight.) When 1.0 mg/kg of


~ ~.




, . . '. ' :
.
.
. .

.





1 morphine was administered intramuscularly to 13 dogs, 12
of them vomited within an average time of 3.5 minutes.

U. S. Patent No. 4,176,186 to myself and others
disclosed treatment of intestinal immobility associated
with the use of narcotic analgesics through the
administration of guaternary derivatives of
noroxymorphone.'' It has now been discovered that the
same compounds are also useful fox the treatment, ~oth
prophylactic.and therapeutic,'of the nausea and vomiting
associated with the administration of these drugs.
'~'According to the invention, therefore, nausea and
vomiting by warm-blooded animals receiving morphine and
lS related opiates~ meperidine,-methadone or the like, may
be prevented ~r relieved by the administration of
methylnaltrexone or other quaternary derivatives of
noroxymorphone represented by the formula:
rA/~ C~13 X




` ~`b
wherein ~/0
R is allyl or a related radical such as
chloroallyl, cyclopropyl-methyl Gr propargyl, and
X is the anion of an acid, especially a chloride,
bromide, iodide or methylsulfate anion.
These compounds are administered to the animal
either prior to or . simultaneously with the
administration of the narcotic analgesic. They may be

~3~
-- 3 ~
admini~-tered either enterally or paren-terally. There has no-t
been observed any interference with the analgesic activi-ty of
the opi~tes.




As used herein, unless the sense of the usage indicates
otherwise, the term l'morphine" refers to any narcotic
analgesic.

This invention relates to the use of quaternary
derivatives of noroxymorphone to prev~nt or relieve nausea
and vomiting associated with the administration of morphine
to warm-blooded animals. The useful compounds are
represented by the formula:
R X
I ~ CH3
r- N




wherein
R is allyl or a related radical such as chloroallyl,
cyclopropyl-methyl or propargyl, and
X is the anion of an acid, especially a chloride,
bromide, iodide or methylsulfate anion.
!
The compounds are synthesized as described in United
5tates Patent No. 4,176,I86. A particularly preferred
noroxymorphone derivative is methylnaltrexone, but other
compounds represented by the above formula are also suitable.
Methylnaltrexone or other noroxymorphone deriva-tives may
be administered to the patient either

-
? ~: 1

'`' ~


'
., ~ . .. .
. . .
,: ~ , . ' "; ' ' , ~ ' ' ' ' " ', ' ' ' '
' ':
'" ' : : '
~ :- ~' . ' :

~3~LS~




1 enterally or parenterally. However, a preferred method
of administration is by injection. Nausea and emesis
may follow after even a single does sf morphine, unlikP
intestinal immobility which is usually the effect of
chronic repeated usage of the drug. Consequently, it is
contemplated that-the patient will be given an injection
of methylnaltrexone prior to surgery or other occasion
when morphine is used to treat acute pain.
As illustrated :-by :~he ~ifollowing Controls and
Examples, our studies show that methylnaltrexone
inhibits emesis when administered either together with
the morphine or before the morphine is administered. It
is thought that methylnaltrexone- or other quaternary
noroxymorphone derivatives may be administered up to two
hours before the administration of morphine, but that
period may be variable. In our studies,
methylnaltrexone was administered intramuscularly by
means of a syringé. Methylnaltrexone may also be
administered enteraIly or parenterally by other means.
It has been found to be effective in dosages in the
range of about 0.05 mg/kg to about 1.0 mg~kg for each 1
mg/kg of administered morphine. It was found effective
when administered in the same syringe as morphine and
also when administered up to about one hour before the
administration of morphine.
The effect of methylnaltrexone in reversing the
emetic effects of morphine is illustrated herein. The
unit of mg/kg refers to milligrams of substance
administered per kilograms of body weight.

. ~ CONTROL 1 AND EXAMPLE_1
one mg/kg of morphine was administered
intramuscularly to five dogs. Four dogs vomited. In
each instance, vomiting occurred within four minutes.
On a different day the same dose of morphine was

~3~5~




--5--
1 administered intramuscularly to the same five dogs in
the same syringe with 1 mg/kg of methylnaltrexone. None
of the dogs vomited.

CONTROL 2 AND EXAMPLE 2
Six dogs were given intramuscular doses of 1 mg/kg
of morphine. All six dogs vomited. On an ~dditional
day the same dose of morphine was combined with 0.5
mg/kg of methylnaltraxone and administered in the same
syringe to the same dogs. None of the dogs vomited.

CONTROL 3 AND EXAMPLE 3
one mg/kg of morphine was administered
intramuscularly to three dogs. All three dogs vomited.
On an additional day the morphine was combined with 0.25
mg/kg of methylnaltrexone and administered in the same
syringe. None of the dogs vomited.

CONTROL 4 AND EXAMPLE 4
Methylnaltrexone was administered to two dogs prior
to the administration of 1 mg/kg morphine. In one dog,
0.5 mg/kg of methylnaltrexone was administered
intramuscularly 15 minutes before the morphine. No
vomiting occurred. In the second dog, the same dose o~
methylnal~rexone was administered 30 minutes before the
administration of morphine. No vomiting occurred.

CONTROL 5 AND EXAMPLE 5
O. 05 mg/kg methylnaltrexone was administered
intravenously to four dogs one minute prior to the
administration of 1.0 mg/kg morphine. No vomiting
occurred in any of the dogs. On a different day, the
same animals were given 1.0 mg/kg morphine without the
administration of methylnaltrexone. All four dogs
3 5 vomited .

~3~6t~
-- 6
The administration of methylnaltrexone alone was found
to produce no noticeable effec-ts in the animals. Previous
studies with larger doses of methylnaltrexone have
demonstrated that unlike the non-quaternary naltrexone,
methylnaltrexone does no-t precipitate withdrawal systems in
morphine-tolerant dogs. Russell et al., Eur~ J. Pharmacol.
78:255-261 ~19823. Methylnaltrexone has not been found -to
interfere with the analgesic activity of morphine or
narcotics.




, . :

Representative Drawing

Sorry, the representative drawing for patent document number 1315689 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 1993-04-06
(22) Filed 1987-10-09
(45) Issued 1993-04-06
Expired 2010-04-06

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Application Fee $0.00 1987-10-09
Registration of a document - section 124 $0.00 1987-12-21
Maintenance Fee - Patent - Old Act 2 1995-04-06 $100.00 1995-03-10
Maintenance Fee - Patent - Old Act 3 1996-04-08 $100.00 1996-03-19
Maintenance Fee - Patent - Old Act 4 1997-04-07 $100.00 1997-03-19
Maintenance Fee - Patent - Old Act 5 1998-04-06 $75.00 1998-03-18
Maintenance Fee - Patent - Old Act 6 1999-04-06 $150.00 1999-03-24
Maintenance Fee - Patent - Old Act 7 2000-04-06 $150.00 2000-03-20
Maintenance Fee - Patent - Old Act 8 2001-04-06 $350.00 2001-04-19
Maintenance Fee - Patent - Old Act 9 2002-04-08 $150.00 2002-03-25
Maintenance Fee - Patent - Old Act 10 2003-04-07 $400.00 2003-05-21
Maintenance Fee - Patent - Old Act 11 2004-04-06 $250.00 2004-04-01
Maintenance Fee - Patent - Old Act 12 2005-04-06 $250.00 2005-03-21
Maintenance Fee - Patent - Old Act 13 2006-04-06 $250.00 2006-03-17
Maintenance Fee - Patent - Old Act 14 2007-04-10 $250.00 2007-03-19
Maintenance Fee - Patent - Old Act 15 2008-04-07 $450.00 2008-03-17
Maintenance Fee - Patent - Old Act 16 2009-04-06 $450.00 2009-03-18
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
UNIVERSITY OF CHICAGO
Past Owners on Record
GOLDBERG, LEON I.
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Description 1993-11-11 6 215
Drawings 1993-11-11 1 16
Claims 1993-11-11 4 84
Abstract 1993-11-11 1 19
Cover Page 1993-11-11 1 16
Correspondence 2004-05-07 1 18
Fees 1997-03-19 1 39
Fees 1996-03-19 1 33
Fees 1995-03-10 1 31
Assignment 1987-10-09 4 188
Correspondence 1993-01-06 1 46
Prosecution-Amendment 1992-06-26 2 51
Prosecution-Amendment 1992-02-28 1 61
Prosecution-Amendment 1991-11-25 2 50
Prosecution-Amendment 1991-11-06 1 38
Prosecution-Amendment 1991-05-07 1 37
Prosecution-Amendment 1990-12-06 2 53
Prosecution-Amendment 1990-08-06 1 49